BioCryst Pharmaceuticals (BCRX) Short Interest Ratio & Short Volume → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free BCRX Stock Alerts $4.16 0.00 (0.00%) (As of 04/26/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability BioCryst Pharmaceuticals Short Interest DataCurrent Short Volume34,390,000 sharesPrevious Short Volume32,250,000 sharesChange Vs. Previous Month+6.64%Dollar Volume Sold Short$160.60 millionShort Interest Ratio / Days to Cover11.0Last Record DateApril 15, 2024Outstanding Shares206,150,000 sharesPercentage of Shares Shorted16.68%Today's Trading Volume2,309,939 sharesAverage Trading Volume3,300,050 sharesToday's Volume Vs. Average70% Short Selling BioCryst Pharmaceuticals ? Sign up to receive the latest short interest report for BioCryst Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatBCRX Short Interest Over TimeBCRX Days to Cover Over TimeBCRX Percentage of Float Shorted Over Time Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now BioCryst Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/202434,390,000 shares $160.60 million +6.6%N/A11 $4.67 3/31/202432,250,000 shares $163.83 million +5.6%N/A9.8 $5.08 3/15/202430,550,000 shares $152.75 million +5.0%N/A9.3 $5.00 2/29/202429,100,000 shares $163.83 million -1.1%N/A7.4 $5.63 2/15/202429,410,000 shares $165.87 million +1.3%N/A7.6 $5.64 1/31/202429,040,000 shares $153.91 million +3.5%N/A7.6 $5.30 Get the Latest News and Ratings for BCRX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for BioCryst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 1/15/202428,050,000 shares $178.12 million -6.8%N/A7.1 $6.35 12/31/202330,080,000 shares $180.18 million +1.0%N/A7.4 $5.99 12/15/202329,780,000 shares $184.34 million +1.4%N/A7.8 $6.19 11/30/202329,380,000 shares $172.75 million -0.3%N/A8.5 $5.88 11/15/202329,470,000 shares $153.54 million -2.2%N/A10.3 $5.21 10/31/202330,130,000 shares $165.41 million -31.8%N/A10.9 $5.49 10/15/202344,190,000 shares $262.49 million +4.3%N/A15.5 $5.94 9/30/202342,390,000 shares $300.12 million -0.3%N/A17 $7.08 9/15/202342,500,000 shares $291.13 million +2.9%N/A16.9 $6.85 8/31/202341,300,000 shares $293.64 million +3.1%N/A16.3 $7.11 8/15/202340,060,000 shares $278.02 million +2.7%N/A15.2 $6.94 7/31/202339,000,000 shares $288.21 million +3.4%N/A14.7 $7.39 7/15/202337,730,000 shares $269.01 million +0.9%N/A14.9 $7.13 6/30/202337,390,000 shares $263.23 million +5.4%N/A13.8 $7.04 6/15/202335,480,000 shares $283.13 million -0.3%N/A12.9 $7.98 5/31/202335,580,000 shares $294.25 million +10.2%N/A13 $8.27 5/15/202332,300,000 shares $283.27 million +3.5%N/A11 $8.77 4/30/202331,200,000 shares $237.43 million +2.8%N/A10.2 $7.61 4/15/202330,360,000 shares $245.01 million -2.8%N/A10.5 $8.07 3/31/202331,220,000 shares $260.37 million +1.3%N/A10.7 $8.34 3/15/202330,810,000 shares $257.88 million +4.5%N/A10.3 $8.37 2/28/202329,480,000 shares $260.90 million +9.2%N/A9.9 $8.85 2/15/202326,990,000 shares $274.22 million +1.2%N/A9.7 $10.16 1/31/202326,680,000 shares $281.47 million +2.2%N/A10.2 $10.55 1/15/202326,110,000 shares $265.28 million -4.2%N/A8.8 $10.16 12/30/202227,240,000 shares $312.72 million -1.6%N/A9.6 $11.48 12/15/202227,680,000 shares $299.22 million +0.3%N/A10.3 $10.81 11/30/202227,610,000 shares $368.87 million -0.9%N/A10.3 $13.36 11/15/202227,870,000 shares $369.00 million +0.9%N/A10.7 $13.24 10/31/202227,630,000 shares $368.86 million -2.3%N/A10.5 $13.35 10/15/202228,290,000 shares $382.76 million +0.6%N/A11 $13.53 9/30/202228,130,000 shares $354.44 million -2.4%N/A10.9 $12.60 9/15/202228,820,000 shares $369.76 million +3.3%N/A10.5 $12.83 8/31/202227,910,000 shares $387.95 million +2.1%N/A9.7 $13.90Claim Your Complimentary Bitcoin Reward (Ad)Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now BCRX Short Interest - Frequently Asked Questions What is BioCryst Pharmaceuticals' current short interest? Short interest is the volume of BioCryst Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of April 15th, investors have sold 34,390,000 shares of BCRX short. Learn More on BioCryst Pharmaceuticals' current short interest. What is a good short interest ratio for BioCryst Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. BCRX shares currently have a short interest ratio of 11.0. Learn More on BioCryst Pharmaceuticals's short interest ratio. Which institutional investors are shorting BioCryst Pharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of BioCryst Pharmaceuticals: Simplex Trading LLC, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is BioCryst Pharmaceuticals' short interest increasing or decreasing? BioCryst Pharmaceuticals saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 34,390,000 shares, an increase of 6.6% from the previous total of 32,250,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does BioCryst Pharmaceuticals' short interest compare to its competitors? Here is how the short interest of companies in the industry of "biological products, except diagnostic" compare to BioCryst Pharmaceuticals: Novavax, Inc. (31.28%), Immatics (10.60%), REGENXBIO Inc. (8.30%), Relay Therapeutics, Inc. (8.08%), CARGO Therapeutics, Inc. (13.21%), Cullinan Oncology, Inc. (6.38%), Vir Biotechnology, Inc. (5.79%), Mesoblast Limited (0.63%), Adaptimmune Therapeutics plc (2.06%), Scholar Rock Holding Co. (16.30%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks. What does it mean to sell short BioCryst Pharmaceuticals stock? Short selling BCRX is an investing strategy that aims to generate trading profit from BioCryst Pharmaceuticals as its price is falling. BCRX shares are trading up $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against BioCryst Pharmaceuticals? A short squeeze for BioCryst Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of BCRX, which in turn drives the price of the stock up even further. How often is BioCryst Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including BCRX, twice per month. The most recent reporting period available is April, 15 2024. More Short Interest Resources from MarketBeat Related Companies: NVAX Short Interest IMTX Short Interest RGNX Short Interest RLAY Short Interest CRGX Short Interest CGEM Short Interest VIR Short Interest MESO Short Interest ADAP Short Interest SRRK Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:BCRX) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”Altimetry